Halozyme Therapeutics Common Stock Net 2010-2025 | HALO

Halozyme Therapeutics common stock net for the quarter ending March 31, 2025 was $0.000B, a 3.15% decline year-over-year.

  • Halozyme Therapeutics common stock net for 2024 was $0B, a 3.15% decline from 2023.
  • Halozyme Therapeutics common stock net for 2023 was $0B, a 5.93% decline from 2022.
  • Halozyme Therapeutics common stock net for 2022 was $0B, a 2.17% decline from 2021.

Halozyme Therapeutics Common Stock Net 2010-2025 | HALO

  • Halozyme Therapeutics common stock net for 2024 was $0B, a 3.15% decline from 2023.
  • Halozyme Therapeutics common stock net for 2023 was $0B, a 5.93% decline from 2022.
  • Halozyme Therapeutics common stock net for 2022 was $0B, a 2.17% decline from 2021.